APO Research
Talk to an analyst

APO RESEARCH · REPORT

Statin

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Statin Market Analysis and Forecast 2026-2032

20 December 2025200 pages

Choose your research edition.

Industry ResearchStatin Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Statin Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Statin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Statin Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Statin Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Statin market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Statin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Statin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Statin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Statin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Statin include CHIA TAI TIANQING, Zhejiang Jingxin Pharmaceutical, Shanghai Shyndec Pharmaceutical, Henan Topfond Pharmaceutical, Novartis, Merck, LUNAN BETTER, Livzon Pharmaceutical and Wanbang Biopharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Statin, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Statin, also provides the revenue of main regions and countries. Of the upcoming market potential for Statin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Statin revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Statin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Statin revenue, projected growth trends, production technology, application and end-user industry.

Statin Segment by Company

CHIA TAI TIANQING

Zhejiang Jingxin Pharmaceutical

Shanghai Shyndec Pharmaceutical

Henan Topfond Pharmaceutical

Novartis

Merck

LUNAN BETTER

Livzon Pharmaceutical

Wanbang Biopharmaceuticals

Pfizer

Huizhi

China Resources Double-Crane Pharmaceutical

North China Pharmaceutical

Hanhui Pharmaceutical

Daiichi Sankyo

Beijing Jialin Pharmaceutical

AstraZeneca

Statin Segment by Type

Astrovastatin

Pitavastatin

Rosuvastatin

Others

Statin Segment by Application

Inflammatory Disorders

Cardiovascular Disorders

Obesity

Others

Statin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Statin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Statin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Statin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Statin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Statin company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Statin revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Statin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Astrovastatin Major Player Table 3. Pitavastatin Major Player Table 4. Rosuvastatin Major Player Table 5. Others Major Player Table 6. Global Statin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Inflammatory Disorders Major Player Table 8. Cardiovascular Disorders Major Player Table 9. Obesity Major Player Table 10. Others Major Player Table 11. Statin Industry Trends Table 12. Statin Industry Drivers Table 13. Statin Industry Opportunities and Challenges Table 14. Statin Industry Restraints Table 15. Global Statin Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Statin Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Statin Market Share by Region (2021-2026) Table 18. Global Statin Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Statin Market Share by Region (2027-2032) Table 20. Global Statin Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Statin Revenue Market Share by Players (2021-2026) Table 22. Global Statin Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Statin Key Players Headquarters & Area Served Table 24. Global Statin Players, Product Type & Application Table 25. Global Statin Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Statin by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Statin Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Statin Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Statin Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Statin Revenue Market Share by Type (2021-2026) Table 32. Global Statin Revenue Market Share by Type (2027-2032) Table 33. Global Statin Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Statin Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Statin Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Statin Revenue Market Share by Application (2021-2026) Table 37. Global Statin Revenue Market Share by Application (2027-2032) Table 38. CHIA TAI TIANQING Company Information Table 39. CHIA TAI TIANQING Business Overview Table 40. CHIA TAI TIANQING Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. CHIA TAI TIANQING Statin Product Portfolio Table 42. CHIA TAI TIANQING Recent Development Table 43. Zhejiang Jingxin Pharmaceutical Company Information Table 44. Zhejiang Jingxin Pharmaceutical Business Overview Table 45. Zhejiang Jingxin Pharmaceutical Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Zhejiang Jingxin Pharmaceutical Statin Product Portfolio Table 47. Zhejiang Jingxin Pharmaceutical Recent Development Table 48. Shanghai Shyndec Pharmaceutical Company Information Table 49. Shanghai Shyndec Pharmaceutical Business Overview Table 50. Shanghai Shyndec Pharmaceutical Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Shanghai Shyndec Pharmaceutical Statin Product Portfolio Table 52. Shanghai Shyndec Pharmaceutical Recent Development Table 53. Henan Topfond Pharmaceutical Company Information Table 54. Henan Topfond Pharmaceutical Business Overview Table 55. Henan Topfond Pharmaceutical Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Henan Topfond Pharmaceutical Statin Product Portfolio Table 57. Henan Topfond Pharmaceutical Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Novartis Statin Product Portfolio Table 62. Novartis Recent Development Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Merck Statin Product Portfolio Table 67. Merck Recent Development Table 68. LUNAN BETTER Company Information Table 69. LUNAN BETTER Business Overview Table 70. LUNAN BETTER Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. LUNAN BETTER Statin Product Portfolio Table 72. LUNAN BETTER Recent Development Table 73. Livzon Pharmaceutical Company Information Table 74. Livzon Pharmaceutical Business Overview Table 75. Livzon Pharmaceutical Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Livzon Pharmaceutical Statin Product Portfolio Table 77. Livzon Pharmaceutical Recent Development Table 78. Wanbang Biopharmaceuticals Company Information Table 79. Wanbang Biopharmaceuticals Business Overview Table 80. Wanbang Biopharmaceuticals Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Wanbang Biopharmaceuticals Statin Product Portfolio Table 82. Wanbang Biopharmaceuticals Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Statin Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Pfizer Statin Product Portfolio Table 87. Pfizer Recent Development Table 88. Huizhi Company Information Table 89. Huizhi Business Overview Table 90. Huizhi Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Huizhi Statin Product Portfolio Table 92. Huizhi Recent Development Table 93. China Resources Double-Crane Pharmaceutical Company Information Table 94. China Resources Double-Crane Pharmaceutical Business Overview Table 95. China Resources Double-Crane Pharmaceutical Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. China Resources Double-Crane Pharmaceutical Statin Product Portfolio Table 97. China Resources Double-Crane Pharmaceutical Recent Development Table 98. North China Pharmaceutical Company Information Table 99. North China Pharmaceutical Business Overview Table 100. North China Pharmaceutical Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. North China Pharmaceutical Statin Product Portfolio Table 102. North China Pharmaceutical Recent Development Table 103. Hanhui Pharmaceutical Company Information Table 104. Hanhui Pharmaceutical Business Overview Table 105. Hanhui Pharmaceutical Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Hanhui Pharmaceutical Statin Product Portfolio Table 107. Hanhui Pharmaceutical Recent Development Table 108. Daiichi Sankyo Company Information Table 109. Daiichi Sankyo Business Overview Table 110. Daiichi Sankyo Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Daiichi Sankyo Statin Product Portfolio Table 112. Daiichi Sankyo Recent Development Table 113. Beijing Jialin Pharmaceutical Company Information Table 114. Beijing Jialin Pharmaceutical Business Overview Table 115. Beijing Jialin Pharmaceutical Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Beijing Jialin Pharmaceutical Statin Product Portfolio Table 117. Beijing Jialin Pharmaceutical Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Statin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. AstraZeneca Statin Product Portfolio Table 122. AstraZeneca Recent Development Table 123. North America Statin Revenue by Type (2021-2026) & (US$ Million) Table 124. North America Statin Revenue by Type (2027-2032) & (US$ Million) Table 125. North America Statin Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Statin Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Statin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. North America Statin Revenue by Country (2021-2026) & (US$ Million) Table 129. North America Statin Revenue by Country (US$ Million) & (2027-2032) Table 130. Europe Statin Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Statin Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Statin Revenue by Application (2021-2026) & (US$ Million) Table 133. Europe Statin Revenue by Application (2027-2032) & (US$ Million) Table 134. Europe Statin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Europe Statin Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Statin Revenue by Country (US$ Million) & (2027-2032) Table 137. China Statin Revenue by Type (2021-2026) & (US$ Million) Table 138. China Statin Revenue by Type (2027-2032) & (US$ Million) Table 139. China Statin Revenue by Application (2021-2026) & (US$ Million) Table 140. China Statin Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia Statin Revenue by Type (2021-2026) & (US$ Million) Table 142. Asia Statin Revenue by Type (2027-2032) & (US$ Million) Table 143. Asia Statin Revenue by Application (2021-2026) & (US$ Million) Table 144. Asia Statin Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Statin Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 146. Asia Statin Revenue by Region (US$ Million) & (2021-2026) Table 147. Asia Statin Revenue by Region (US$ Million) & (2027-2032) Table 148. SAMEA Statin Revenue by Type (2021-2026) & (US$ Million) Table 149. SAMEA Statin Revenue by Type (2027-2032) & (US$ Million) Table 150. SAMEA Statin Revenue by Application (2021-2026) & (US$ Million) Table 151. SAMEA Statin Revenue by Application (2027-2032) & (US$ Million) Table 152. SAMEA Statin Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. SAMEA Statin Revenue by Country (2021-2026) & (US$ Million) Table 154. SAMEA Statin Revenue by Country (US$ Million) & (2027-2032) Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Statin Image Figure 2. Global Statin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Statin Market Size Share 2021 VS 2025 VS 2032 Figure 4. Astrovastatin Image Figure 5. Pitavastatin Image Figure 6. Rosuvastatin Image Figure 7. Others Image Figure 8. Global Statin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Statin Market Size Share 2021 VS 2025 VS 2032 Figure 10. Inflammatory Disorders Image Figure 11. Cardiovascular Disorders Image Figure 12. Obesity Image Figure 13. Others Image Figure 14. Global Statin Market Size (US$ Million) & (2021-2032) Figure 15. Global Statin Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Statin Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Statin Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Statin Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Statin Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Statin Revenue Market Share by Type (2021-2032) Figure 22. Global Statin Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Statin Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Statin Revenue Market Share by Application (2021-2032) Figure 25. North America Statin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Statin Revenue Share by Type (2021-2032) Figure 27. North America Statin Revenue Share by Application (2021-2032) Figure 28. North America Statin Revenue Share by Country (2021-2032) Figure 29. United States Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Statin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Statin Revenue Share by Type (2021-2032) Figure 34. Europe Statin Revenue Share by Application (2021-2032) Figure 35. Europe Statin Revenue Share by Country (2021-2032) Figure 36. Germany Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Statin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Statin Revenue Share by Type (2021-2032) Figure 46. China Statin Revenue Share by Application (2021-2032) Figure 47. Asia Statin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Statin Revenue Share by Type (2021-2032) Figure 49. Asia Statin Revenue Share by Application (2021-2032) Figure 50. Asia Statin Revenue Share by Region (2021-2032) Figure 51. Japan Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Statin Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Statin Revenue Share by Type (2021-2032) Figure 59. SAMEA Statin Revenue Share by Application (2021-2032) Figure 60. SAMEA Statin Revenue Share by Country (2021-2032) Figure 61. Brazil Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Statin Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Astrovastatin
  • Pitavastatin
  • Rosuvastatin
  • Others
Applications
  • Inflammatory Disorders
  • Cardiovascular Disorders
  • Obesity
  • Others
Companies covered
  • CHIA TAI TIANQING
  • Zhejiang Jingxin Pharmaceutical
  • Shanghai Shyndec Pharmaceutical
  • Henan Topfond Pharmaceutical
  • Novartis
  • Merck
  • LUNAN BETTER
  • Livzon Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Pfizer
  • Huizhi
  • China Resources Double-Crane Pharmaceutical
  • North China Pharmaceutical
  • Hanhui Pharmaceutical
  • Daiichi Sankyo
  • Beijing Jialin Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Statin Market by Type
  3. 1.2.1 Global Statin Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Astrovastatin
  5. 1.2.3 Pitavastatin
  6. 1.2.4 Rosuvastatin
  7. 1.2.5 Others
  8. 1.3 Statin Market by Application
  9. 1.3.1 Global Statin Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Inflammatory Disorders
  11. 1.3.3 Cardiovascular Disorders
  12. 1.3.4 Obesity
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Statin Market Dynamics
  1. 2.1 Statin Industry Trends
  2. 2.2 Statin Industry Drivers
  3. 2.3 Statin Industry Opportunities and Challenges
  4. 2.4 Statin Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Statin Market Perspective (2021-2032)
  2. 3.2 Global Statin Growth Trends by Region
  3. 3.2.1 Global Statin Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Statin Market Size by Region (2021-2026)
  5. 3.2.3 Global Statin Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Statin Revenue by Players
  2. 4.1.1 Global Statin Revenue by Players (2021-2026)
  3. 4.1.2 Global Statin Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Statin Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Statin Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Statin Key Players Headquarters & Area Served
  7. 4.4 Global Statin Players, Product Type & Application
  8. 4.5 Global Statin Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Statin Market CR5 and HHI
  11. 4.6.3 2025 Statin Tier 1, Tier 2, and Tier 3
5 Statin Market Size by Type
  1. 5.1 Global Statin Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Statin Revenue by Type (2021-2032)
  3. 5.3 Global Statin Revenue Market Share by Type (2021-2032)
6 Statin Market Size by Application
  1. 6.1 Global Statin Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Statin Revenue by Application (2021-2032)
  3. 6.3 Global Statin Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 CHIA TAI TIANQING
  2. 7.1.1 CHIA TAI TIANQING Company Information
  3. 7.1.2 CHIA TAI TIANQING Business Overview
  4. 7.1.3 CHIA TAI TIANQING Statin Revenue and Gross Margin (2021-2026)
  5. 7.1.4 CHIA TAI TIANQING Statin Product Portfolio
  6. 7.1.5 CHIA TAI TIANQING Recent Developments
  7. 7.2 Zhejiang Jingxin Pharmaceutical
  8. 7.2.1 Zhejiang Jingxin Pharmaceutical Company Information
  9. 7.2.2 Zhejiang Jingxin Pharmaceutical Business Overview
  10. 7.2.3 Zhejiang Jingxin Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Zhejiang Jingxin Pharmaceutical Statin Product Portfolio
  12. 7.2.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  13. 7.3 Shanghai Shyndec Pharmaceutical
  14. 7.3.1 Shanghai Shyndec Pharmaceutical Company Information
  15. 7.3.2 Shanghai Shyndec Pharmaceutical Business Overview
  16. 7.3.3 Shanghai Shyndec Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Shyndec Pharmaceutical Statin Product Portfolio
  18. 7.3.5 Shanghai Shyndec Pharmaceutical Recent Developments
  19. 7.4 Henan Topfond Pharmaceutical
  20. 7.4.1 Henan Topfond Pharmaceutical Company Information
  21. 7.4.2 Henan Topfond Pharmaceutical Business Overview
  22. 7.4.3 Henan Topfond Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Henan Topfond Pharmaceutical Statin Product Portfolio
  24. 7.4.5 Henan Topfond Pharmaceutical Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Statin Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Statin Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Merck
  32. 7.6.1 Merck Company Information
  33. 7.6.2 Merck Business Overview
  34. 7.6.3 Merck Statin Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck Statin Product Portfolio
  36. 7.6.5 Merck Recent Developments
  37. 7.7 LUNAN BETTER
  38. 7.7.1 LUNAN BETTER Company Information
  39. 7.7.2 LUNAN BETTER Business Overview
  40. 7.7.3 LUNAN BETTER Statin Revenue and Gross Margin (2021-2026)
  41. 7.7.4 LUNAN BETTER Statin Product Portfolio
  42. 7.7.5 LUNAN BETTER Recent Developments
  43. 7.8 Livzon Pharmaceutical
  44. 7.8.1 Livzon Pharmaceutical Company Information
  45. 7.8.2 Livzon Pharmaceutical Business Overview
  46. 7.8.3 Livzon Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Livzon Pharmaceutical Statin Product Portfolio
  48. 7.8.5 Livzon Pharmaceutical Recent Developments
  49. 7.9 Wanbang Biopharmaceuticals
  50. 7.9.1 Wanbang Biopharmaceuticals Company Information
  51. 7.9.2 Wanbang Biopharmaceuticals Business Overview
  52. 7.9.3 Wanbang Biopharmaceuticals Statin Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Wanbang Biopharmaceuticals Statin Product Portfolio
  54. 7.9.5 Wanbang Biopharmaceuticals Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Statin Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Statin Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Huizhi
  62. 7.11.1 Huizhi Company Information
  63. 7.11.2 Huizhi Business Overview
  64. 7.11.3 Huizhi Statin Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Huizhi Statin Product Portfolio
  66. 7.11.5 Huizhi Recent Developments
  67. 7.12 China Resources Double-Crane Pharmaceutical
  68. 7.12.1 China Resources Double-Crane Pharmaceutical Company Information
  69. 7.12.2 China Resources Double-Crane Pharmaceutical Business Overview
  70. 7.12.3 China Resources Double-Crane Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  71. 7.12.4 China Resources Double-Crane Pharmaceutical Statin Product Portfolio
  72. 7.12.5 China Resources Double-Crane Pharmaceutical Recent Developments
  73. 7.13 North China Pharmaceutical
  74. 7.13.1 North China Pharmaceutical Company Information
  75. 7.13.2 North China Pharmaceutical Business Overview
  76. 7.13.3 North China Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  77. 7.13.4 North China Pharmaceutical Statin Product Portfolio
  78. 7.13.5 North China Pharmaceutical Recent Developments
  79. 7.14 Hanhui Pharmaceutical
  80. 7.14.1 Hanhui Pharmaceutical Company Information
  81. 7.14.2 Hanhui Pharmaceutical Business Overview
  82. 7.14.3 Hanhui Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Hanhui Pharmaceutical Statin Product Portfolio
  84. 7.14.5 Hanhui Pharmaceutical Recent Developments
  85. 7.15 Daiichi Sankyo
  86. 7.15.1 Daiichi Sankyo Company Information
  87. 7.15.2 Daiichi Sankyo Business Overview
  88. 7.15.3 Daiichi Sankyo Statin Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Daiichi Sankyo Statin Product Portfolio
  90. 7.15.5 Daiichi Sankyo Recent Developments
  91. 7.16 Beijing Jialin Pharmaceutical
  92. 7.16.1 Beijing Jialin Pharmaceutical Company Information
  93. 7.16.2 Beijing Jialin Pharmaceutical Business Overview
  94. 7.16.3 Beijing Jialin Pharmaceutical Statin Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Beijing Jialin Pharmaceutical Statin Product Portfolio
  96. 7.16.5 Beijing Jialin Pharmaceutical Recent Developments
  97. 7.17 AstraZeneca
  98. 7.17.1 AstraZeneca Company Information
  99. 7.17.2 AstraZeneca Business Overview
  100. 7.17.3 AstraZeneca Statin Revenue and Gross Margin (2021-2026)
  101. 7.17.4 AstraZeneca Statin Product Portfolio
  102. 7.17.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Statin Revenue (2021-2032)
  2. 8.2 North America Statin Revenue by Type (2021-2032)
  3. 8.2.1 North America Statin Revenue by Type (2021-2026)
  4. 8.2.2 North America Statin Revenue by Type (2027-2032)
  5. 8.3 North America Statin Revenue Share by Type (2021-2032)
  6. 8.4 North America Statin Revenue by Application (2021-2032)
  7. 8.4.1 North America Statin Revenue by Application (2021-2026)
  8. 8.4.2 North America Statin Revenue by Application (2027-2032)
  9. 8.5 North America Statin Revenue Share by Application (2021-2032)
  10. 8.6 North America Statin Revenue by Country
  11. 8.6.1 North America Statin Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Statin Revenue by Country (2021-2026)
  13. 8.6.3 North America Statin Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Statin Revenue (2021-2032)
  2. 9.2 Europe Statin Revenue by Type (2021-2032)
  3. 9.2.1 Europe Statin Revenue by Type (2021-2026)
  4. 9.2.2 Europe Statin Revenue by Type (2027-2032)
  5. 9.3 Europe Statin Revenue Share by Type (2021-2032)
  6. 9.4 Europe Statin Revenue by Application (2021-2032)
  7. 9.4.1 Europe Statin Revenue by Application (2021-2026)
  8. 9.4.2 Europe Statin Revenue by Application (2027-2032)
  9. 9.5 Europe Statin Revenue Share by Application (2021-2032)
  10. 9.6 Europe Statin Revenue by Country
  11. 9.6.1 Europe Statin Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Statin Revenue by Country (2021-2026)
  13. 9.6.3 Europe Statin Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Statin Revenue (2021-2032)
  2. 10.2 China Statin Revenue by Type (2021-2032)
  3. 10.2.1 China Statin Revenue by Type (2021-2026)
  4. 10.2.2 China Statin Revenue by Type (2027-2032)
  5. 10.3 China Statin Revenue Share by Type (2021-2032)
  6. 10.4 China Statin Revenue by Application (2021-2032)
  7. 10.4.1 China Statin Revenue by Application (2021-2026)
  8. 10.4.2 China Statin Revenue by Application (2027-2032)
  9. 10.5 China Statin Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Statin Revenue (2021-2032)
  2. 11.2 Asia Statin Revenue by Type (2021-2032)
  3. 11.2.1 Asia Statin Revenue by Type (2021-2026)
  4. 11.2.2 Asia Statin Revenue by Type (2027-2032)
  5. 11.3 Asia Statin Revenue Share by Type (2021-2032)
  6. 11.4 Asia Statin Revenue by Application (2021-2032)
  7. 11.4.1 Asia Statin Revenue by Application (2021-2026)
  8. 11.4.2 Asia Statin Revenue by Application (2027-2032)
  9. 11.5 Asia Statin Revenue Share by Application (2021-2032)
  10. 11.6 Asia Statin Revenue by Country
  11. 11.6.1 Asia Statin Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Statin Revenue by Country (2021-2026)
  13. 11.6.3 Asia Statin Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Statin Revenue (2021-2032)
  2. 12.2 SAMEA Statin Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Statin Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Statin Revenue by Type (2027-2032)
  5. 12.3 SAMEA Statin Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Statin Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Statin Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Statin Revenue by Application (2027-2032)
  9. 12.5 SAMEA Statin Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Statin Revenue by Country
  11. 12.6.1 SAMEA Statin Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Statin Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Statin Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst